Actually many front-line doctors have been using a multidrug treatment based on existing medicines to successfully reduce hospitalization and death since very early on in the pandemic. One key aspect is treating patients early in the symptomatic phase with a combination of antiviral, corticosteroid, and antithrombotic medications. [1][2][3][4][5][6][7][8][9][10]

Many clinical trials have evaluated the suggested drugs in a single-drug treatment regime, but very few clinical trials have evaluated a multidrug treatment approach specifically focused on patients who are early in the symptomatic phase.

[1] Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection https://www.amjmed.com/article/S0002-9343(20)30673-2/fulltex...

[2] Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?a...

[3] Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection https://rcm.imrpress.com/EN/article/downloadArticleFile.do?a...

[4] Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents https://www.sciencedirect.com/science/article/abs/pii/S03069...

[5] Multidrug treatment for COVID-19 https://www.jstage.jst.go.jp/article/ddt/advpub/0/advpub_202...

[6] A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237953/

[7] Clofazimine broadly inhibits coronaviruses including SARS-CoV-2 https://www.nature.com/articles/s41586-021-03431-4

[8] In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2’s Main Protease https://pubs.acs.org/doi/pdf/10.1021/acs.jpclett.0c00994

[9] Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.0c00521

[10] Repurposed Drugs, Molecular Vaccines, Immune‐Modulators, and Nanotherapeutics to Treat and Prevent COVID‐19 Associated with SARS‐CoV‐2, a Deadly Nanovector https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645867/